HBM gets health boost from drug licensing deals
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer Key Takeaways: Nona Biosciences, a subsidiary of…
HBM rises from the ashes as a research partner for drug giants
The cash-strapped company disposed of a factory and an advanced drug pipeline to stay in business, and is now re-positioning itself as a supplier of biomedical services Key Takeaways: HBM…
After 2022 Slowdown, WuXi Biologics Gets Growth Medicine From Big New Order
China’s leading provider of outsourced medical services said its profit and revenue rose 48.4% and 30% last year, respectively, marking a significant slowdown from the previous yearKey Takeaways:WuXi Biologics revenue…
Surging Beigene Catches Case of Forex Flu
The drug maker’s net loss grew in the third quarter due to weakness in the Chinese yuan, even as its revenue nearly doubledKey Takeaways:Surging sales for its two self-developed drugs…
RELATED ARTICLES
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
-
Everest reaches new heights on growing drug sales
1952.HK
